HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Davies, F. E. Articles by Morgan, G. J. Search for Related Content PubMed PubMed Citation Articles by Davies, F. E. Articles by Morgan, G. J.

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

The Royal Marsden Hospital, London, UK

Correspondence: Faith Davies, Haemato-oncology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK. Phone: international +44.208.6613670. Fax: international +44.208.6429634. E-mail: faith.davies{at}icr.ac.uk

The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.

Key words: cyclophosphamide, velcade and dexamethasone (CVD), comparable toxicity, high response rates.